Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)

BJU International

Volumn 115, Issue 2, 2015, Pages 308-316

  Kozminski, Michael A ^a   Wei, John T ^a   Nelson, Jason ^b   Kent, David M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

benign prostatic hyperplasia (BPH); lower urinary tract symptoms (LUTS); risk factors

Indexed keywords

DOXAZOSIN; FINASTERIDE; PLACEBO; AZASTEROID; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGE; AGED; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ARTICLE; BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX SCORE; CONTROLLED STUDY; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; URINE FLOW RATE; BLOOD; COMBINATION DRUG THERAPY; DISEASE COURSE; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATIC HYPERPLASIA; RISK FACTOR; TREATMENT OUTCOME; URINARY RETENTION;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RISK FACTORS; TREATMENT OUTCOME; URINARY RETENTION;

EID: 84921561393     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12802     Document Type: Article

References (28)

1. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC,. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12-17
2. Jacobsen SJ, Girman CJ, Lieber MM,. Natural history of benign prostatic hyperplasia. Urology 2001; 58 (Suppl. 1): 5-16
3. Maserejian NN, Chen S, Chiu GR, et al. Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample. J Urol 2014; 191: 107-113
4. Martin S, Lange K, Haren MT, et al. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol 2014; 191: 130-137
5. Roehrborn CG,. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008; 101 (Suppl. 3): 17-21
6. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398
7. Anderson JB, Roehrborn CG, Schalken JA, Emberton M,. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001; 39: 390-399
8. Slawin KM, Kattan MW,. The use of nomograms for selecting BPH candidates for dutasteride therapy. Rev Urol 2004; 6 (Suppl. 9): S40-45
9. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175: 1422-1427
10. Roehrborn CG, Siami P, Barkin J, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009; 55: 461-471
11. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA,. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 2010; 11: 85
12. Dorresteijn JA, Visseren FL, Ridker PM, et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ 2011; 343: d5888
13. Burke JF, Hayward RA, Nelson JP, Kent DM,. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes 2014; 7: 163-169
14. Cuticchia AJ, Cooley PC, Hall RD, Qin Y,. NIDDK data repository: a central collection of clinical trial data. BMC Med Inform Decis Mak 2006; 6: 19
15. Slawin KM, Kattan MW, Roehrborn CG, Wilson T,. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urology 2006; 67: 84-88
16. Lowe FC, Batista J, Berges R, et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer Prostatic Dis 2005; 8: 206-209
17. Barry MJ, Fowler FJ, Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK,. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care 1995; 33 (Suppl).): AS145-155
18. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-1557; discussion 1564
19. Roehrborn CG,. Definition of at-risk patients: baseline variables. BJU Int 2006; 97 (Suppl. 2): 7-11; discussion 21-12
20. Trachtenberg J,. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression. BJU Int 2005; 95 (Suppl. 4): 6-11
21. Hong SJ, Ko WJ, Kim SI, Chung BH,. Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol 2003; 44: 94-100
22. Kok ET, Schouten BW, Bohnen AM, et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol 2009; 181: 710-716
23. Parsons JK,. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007; 178: 395-401
24. Steyerberg EW, SpringerLink. Clinical Prediction Models A Practical Approach to Development, Validation, and Updating. New York, NY: Springer-Verlag New York, 2009
25. D'Agostino R, Nam B,. Evaluation of the Performance of Survival Analysis Models: Discrimination and Calibration Measures. Amsterdam, The Netherlands: Elsevier, 2004
26. Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S,. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int 2007; 100: 249-253
27. Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006; 175: 217-221
28. Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-480